News

PD-1/PD-L1 interaction blocked by antibodies, freeing T cell to kill tumor cell

Time: 2017-05-25 15:45:35

PD-1/PD-L1 interaction blocked by antibodies, freeing T cell to kill tumor cell

www.fn-test.com  2017-05-25




KEYTRUDA (anti-PD-1(Programmed cell death protein 1) antibody) get approval of FDA.
 
KEYTRUDA, Also called Pembrolizumab, is an anti-PD-1(Programmed cell death protein 1) antibody from humanized( from Mouse),  which has been approved by the FDA.
 
KEYTRUDA Could inhibit the PD-1/PD-L1 pathway in the body and helps the body’s immune system fight cancer cells. PD-1/PD-L1 interaction blocked by antibodies, freeing T cell to kill tumor cell.
 
MSI-H and dMMR tumor is a genetic abnormality could cause the Affecting the intracellular DNA repair mechanism, PD-1/PD-L1 antibodies could be used to treat the Head and neck cancer; Hodgkin’s disease; Malignant melanoma; Non-small cell lung cancer.
 
Reference
1. “Pembrolizumab”. AdisInsight. Retrieved 5 November 2016.
Related Products
2. Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma, 15 Mar 2017, FDA
 
Fine Test Related Products
EH0252    Human PD-1/PDCD1(Programmed Cell Death Protein 1) ELISA Kit         0.156-10ng/ml
EH2218    Human PDCD4(Programmed cell death protein 4) ELISA Kit          0.312-20ng/ml

Service

点击这里给我发消息

Hotline

027-87384275